VBIX.NASDAQViewbix INC

DEF 14C: Viewbix Shareholders Approve Key Corporate Actions

Sentiment:

Information Statement


Viewbix Inc. stockholders approved a significant share issuance, re-election of current directors, and discretionary authority for a reverse stock split to maintain Nasdaq listing compliance and attract institutional investors.

Capital raiseA private placement offering of 800,000 shares of Common Stock or PIPE Pre-Funded Warrants, along with warrants to purchase up to 640,000 shares, at a combined purchase price of $1.75 per share/warrant or $1.7499 per pre-funded warrant/warrant.Expected gross proceeds of approximately $1.4 million from the private placement, with an additional $1.68 million if all common warrants are exercised in cash.The company will pay a $70,000 cash fee and issue a warrant for 32,000 shares to L.I.A. Pure Capital Ltd. for advisory services related to the private placement.Repayment of $200,000 of an outstanding loan to L.I.A. Pure Capital Ltd. upon the closing of the Private Placement Offering, stemming from a July 22, 2024 facility agreement where it was a lender.

Summary

  • Majority stockholders approved the issuance of up to 20,488,442 shares of Common Stock, consisting of 800,000 Private Placement Shares (or PIPE Pre-Funded Warrants), 640,000 shares from Common Warrants, 32,000 shares from Advisor Warrants, and 19,016,442 shares from the Exchange Agreement.
  • The re-election of the current board members (Amitay Weiss, Ronen Rosenbloom, Eliyahu Yoresh, Alon Dayan, Kineret Tzedef) was approved.
  • Discretionary authority was granted to the Board for a reverse stock split at a ratio between 1-for-2 and 1-for-20, to be completed no later than the two-year anniversary of the Information Statement Effective Date.
  • The reverse stock split aims to increase the per-share price to meet Nasdaq listing requirements ($1.00 minimum bid price) and make the stock more attractive to institutional investors.
  • The Private Placement Offering is expected to generate approximately $1.4 million in gross proceeds, with an additional $1.68 million if all warrants are exercised in cash.
  • The company is acquiring up to 100% (but not less than 85%) of Quantum X Labs Ltd. (Quantum) share capital, issuing up to 40.0% of its own capital stock to Quantum shareholders, plus potential earn-out securities of up to 12,702,847 shares based on milestones.

Sentiment

Score: 6

Explanation: The filing outlines proactive corporate actions to address Nasdaq listing compliance and facilitate a strategic acquisition in the quantum sector, which are generally positive. However, the necessity of a reverse stock split and the significant potential dilution from the share issuance introduce elements of concern, balancing the overall sentiment.

Positives

  • Strategic acquisition of Quantum X Labs Ltd. could expand business into the quantum sector, a high-growth area.
  • Capital raise through a private placement provides approximately $1.4 million in gross proceeds, with potential for an additional $1.68 million from warrant exercises.
  • Proactive steps, including the proposed reverse stock split, are being taken to maintain Nasdaq listing compliance and potentially attract a broader institutional investor base.

Negatives

  • The necessity of a reverse stock split often indicates a low stock price, which can be perceived as a negative signal to the market.
  • The approval for the issuance of up to 20,488,442 shares represents significant potential dilution for existing shareholders, given 10,670,392 shares were outstanding as of the Record Date.
  • The reverse stock split may not guarantee a sustained increase in share price or improved liquidity, and the total market capitalization could decrease.

Risks

  • There is no assurance that the reverse stock split, if completed, will result in the intended benefits, such as a sustained increase in market price or maintenance of Nasdaq compliance.
  • The market price per share of Common Stock after the reverse stock split may not increase proportionally to the reduction in the number of shares outstanding, potentially leading to a lower total market capitalization.
  • A reduction in the number of outstanding shares may impair liquidity for the Common Stock.
  • The reverse stock split could have an anti-takeover effect by increasing authorized but unissued shares, potentially discouraging unsolicited takeover attempts.
  • Stockholders owning odd lots (less than 100 shares) after the split may find their shares more difficult to sell, and brokerage commissions and other transaction costs may be higher.

Future Outlook

The company anticipates the Private Placement Offering to close in the first quarter of 2026 and the acquisition of Quantum X Labs Ltd. to close within 90 calendar days of December 15, 2025. The Board has discretionary authority to effect a reverse stock split within a 1-for-2 to 1-for-20 range within two years to meet Nasdaq listing requirements and attract institutional investors. Earn-out securities related to the Quantum acquisition may be issued upon achievement of specific patent, portfolio company, and capital raise/M&A milestones over the next 12 to 48 months.

Management Comments

  • The Board unanimously adopted, approved and recommended the approval of the Issuance Proposal, Director Election Proposal and Reverse Stock Split Proposal and determined that the approval of each of these proposals is advisable and in the best interests of the Corporation and its stockholders.

Industry Context

The company's actions, particularly the proposed reverse stock split, reflect a common challenge faced by smaller public companies in maintaining compliance with Nasdaq's minimum bid price requirement. The acquisition of Quantum X Labs Ltd. signals a strategic pivot or expansion into the quantum technology sector, aligning with broader industry trends of innovation and diversification, potentially positioning the company in a high-growth area.

Comparison to Industry Standards

  • NA

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Amendment to Certificate of IncorporationGranting discretionary authority to the Board to effect one or more reverse stock splits of Common Stock at a ratio between 1-for-2 and 1-for-20.No later than two year anniversary of Information Statement Effective Date (for completion of split)Aims to increase per share price for Nasdaq compliance and attract institutional investors, but also increases authorized unissued shares which could have anti-takeover effects.
Board of Directors Re-electionRe-election of current Class I, Class II, and Class III directors (Amitay Weiss, Ronen Rosenbloom, Eliyahu Yoresh, Alon Dayan, Kineret Tzedef) to serve their respective staggered terms.January 2, 2026 (approved by written consent)Ensures continuity of current board leadership and oversight.

Related Party Transactions

  • Eliyahu Yoresh, Chairman of the Board, holds approximately 4.24% of Quantum X Labs Ltd. and will receive up to 267,834 shares of common stock and pre-funded warrants of Viewbix Common Stock upon the closing of the Acquisition and the achievement of earn-out milestones.
  • L.I.A. Pure Capital Ltd., a significant stockholder (43.87% beneficial ownership), is the advisor for the Private Placement Offering, receiving a $70,000 cash fee and a warrant to purchase 32,000 shares.
  • L.I.A. Pure Capital Ltd. will also receive a $200,000 loan repayment upon the closing of the Private Placement Offering, stemming from an Amended and Restated Facility Agreement dated July 22, 2024, where it was a lender.
  • Amitay Weiss, a director, is the Chief Executive Officer of Gix Internet Ltd., which is a 26.86% beneficial owner of Viewbix.
  • Eliyahu Yoresh, Chairman of the Board, is also the chairman of the board of directors of Gix Internet Ltd.
  • Amihay Hadad, Chief Executive Officer, and Shahar Marom, Chief Financial Officer, have beneficial ownership including warrants and convertible debt from credit facilities entered into in June and July 2024.

Stakeholder Impact

  • Shareholders: Potential for increased share price and liquidity if the reverse stock split is successful; potential dilution from significant share issuance; potential anti-takeover effect from increased authorized shares; fractional share treatment (cash or rounding up).
  • Investors (Private Placement): Will receive shares/warrants at a combined purchase price of $1.75 or $1.7499, with registration rights.
  • Quantum Shareholders: Will receive Viewbix shares/warrants in exchange for Quantum shares, with potential for earn-out securities based on milestones.
  • Employees/Management: Continuity of current board members; Eliyahu Yoresh has a direct interest in the Quantum acquisition.

Next Steps

  • Mailing of the Information Statement to stockholders on or about January 16, 2026.
  • Private Placement Offering expected to close during the first quarter of 2026.
  • Acquisition of Quantum X Labs Ltd. expected to close within 90 calendar days of December 15, 2025.
  • Filing of a resale registration statement within 30 calendar days after the Private Placement Closing Date.
  • Registration Statement to be declared effective within 60 or 90 calendar days after filing.
  • Board to determine the exact ratio and timing for the reverse stock split, to be completed no later than two years from the Information Statement Effective Date.
  • Potential issuance of earn-out securities to Quantum shareholders upon achievement of specific milestones over the next 12 to 48 months.

Key Dates

DateDescription
August 16, 1985Corporation originally incorporated as The Infergene Company.
March 14, 2018Alon Dayan joined the board of directors.
September 19, 2022Amitay Weiss and Eliyahu Yoresh joined the board of directors.
September 2025Kineret Tzedef and Ronen Rosenbloom joined the board of directors.
November 5, 2025Corporation entered into the original securities purchase agreement and registration rights agreement.
December 15, 2025Corporation entered into the Securities Exchange Agreement (SEA Effective Date).
January 1, 2026Corporation entered into a new securities purchase agreement with investors.
January 2, 2026Majority Stockholders approved actions by written consent.
January 6, 2026Record Date for stockholders.
January 15, 2026Filing date of the Information Statement with the SEC.
January 16, 2026Anticipated mailing date of the Information Statement to stockholders.
First quarter of 2026Expected closing of the Private Placement Offering.
Within 90 calendar days of December 15, 2025Expected closing of the Acquisition of Quantum X Labs Ltd.
Within 30 calendar days after Closing DateCorporation required to file a resale registration statement.
Within 60 or 90 calendar days after Filing DateRegistration Statement to be declared effective.
12-month anniversary of Closing DateEarn-Out Securities may become issuable.
18-month period following Closing DateMilestone for 1,975,998 Earn-Out Securities (patent applications).
24-month period following Closing DateMilestone for 3,436,519 Earn-Out Securities (Portfolio Company listing/M&A).
48-month period following Closing DateMilestone for 7,290,330 Earn-Out Securities (capital raise or Quantum M&A).
Two year anniversary of Information Statement Effective DateDeadline for Reverse Stock Split completion.

Recommendation

hold

The company is undertaking significant corporate actions, including a strategic acquisition and a capital raise, which could be positive long-term. However, the necessity of a reverse stock split to maintain Nasdaq compliance and the substantial potential dilution from the share issuance introduce near-term uncertainties and risks. A 'hold' recommendation allows investors to observe the execution of these initiatives and their impact on the company's financial performance and market valuation before making further investment decisions.

Keywords

Viewbix Inc., VBIX, SEC Filing, DEF 14C, Share Issuance, Private Placement, Warrants, Acquisition, Quantum X Labs, Reverse Stock Split, Nasdaq Listing, Corporate Governance, Board Re-election, Capital Raise, Dilution, Stockholder Approval

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.